Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis (2025)
https://pubmed.ncbi.nlm.nih.gov/39608666/

Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased (2025)
https://pubmed.ncbi.nlm.nih.gov/40021967/

The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs (2025)
https://pubmed.ncbi.nlm.nih.gov/40199504/

Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs (2025)
https://pubmed.ncbi.nlm.nih.gov/40199508/

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis real-world patients treated with secukinumab for 24 months. (2024)
https://pubmed.ncbi.nlm.nih.gov/38301349/

ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis – are they interchangeable? (2024)
https://pubmed.ncbi.nlm.nih.gov/38621792/

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: A European routine-care observational study (2024)
https://pubmed.ncbi.nlm.nih.gov/39053949/

British Axial Spondyloarthritis Inception Cohort (BAxSIC): A protocol for a multicentre real world observational cohort study of early axial Spondyloarthritis. (2024)
https://pubmed.ncbi.nlm.nih.gov/39165398/

Recording of non-musculoskeletal manifestations, comorbidities, and safety outcomes in European spondyloarthritis registries: a survey. (2024)
https://pubmed.ncbi.nlm.nih.gov/39611201/

The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents: BSRBR-AS and meta-analysis (2023)
https://pubmed.ncbi.nlm.nih.gov/35777821/

One-third of European axial spondyloarthritis patients reach pain “remission” with routine care TNF-inhibitor treatment (2023)
https://pubmed.ncbi.nlm.nih.gov/36455943/

The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBR-AS registry. (2022)
https://pubmed.ncbi.nlm.nih.gov/33140891/

Enabling work participation for people with musculoskeletal conditions: lessons from work changes imposed by COVID-19: a mixed-method study. (2022)
https://pubmed.ncbi.nlm.nih.gov/35393323/

Lessons from experiences of accessing healthcare during the pandemic for remobilising rheumatology services: a national mixed methods study. (2022)
https://pubmed.ncbi.nlm.nih.gov/35350717/

Driving difficulties in patients with axial spondyloarthritis: results from the Scotland Registry for Ankylosing Spondylitis. (2022)
https://pubmed.ncbi.nlm.nih.gov/33734612/

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. (2022)
https://pubmed.ncbi.nlm.nih.gov/34940840/

Generating EQ‑5D‑5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data (2022)
https://pubmed.ncbi.nlm.nih.gov/35113270/

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA Collaboration (2022)
https://pubmed.ncbi.nlm.nih.gov/35985172/

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. (2021)
https://pubmed.ncbi.nlm.nih.gov/33331904/

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. (2021)
https://pubmed.ncbi.nlm.nih.gov/34161253/

The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. (2021)
https://pubmed.ncbi.nlm.nih.gov/34469570/

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. (2021)
https://pubmed.ncbi.nlm.nih.gov/33369676/

The effect of COVID19 public health restrictions on the health of people with musculoskeletal conditions and symptoms: the CONTAIN study. (2021)
https://pubmed.ncbi.nlm.nih.gov/34009314/

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. (2021)
https://pubmed.ncbi.nlm.nih.gov/33713118/

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. (2021)
https://pubmed.ncbi.nlm.nih.gov/33502476/

Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). (2020)
https://pubmed.ncbi.nlm.nih.gov/31662321/

Impact of smoking in response to tumor necrosis factor inhibitors in axial spondyloarthritis: methodologic considerations for longitudinal observational studies. (2020)
https://pubmed.ncbi.nlm.nih.gov/30762311/

Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? (2020)
https://pubmed.ncbi.nlm.nih.gov/32327428/

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32641447/

The prevalence of fibromyalgia in axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32556474/

Impact of discordance between patient’s and evaluator’s global on TNFi retention and remission in 14868 spondyloarthritis patients. (2020)
https://pubmed.ncbi.nlm.nih.gov/31960053/

Predicting response to anti-TNFα therapy amongst patients with axial spondyloarthritis (axSpA); results from BSRBR-AS. (2020)
https://pubmed.ncbi.nlm.nih.gov/31990352/

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: Results from the BSRBR-AS registry and meta-analysis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32337555/